Universitair Ziekenhuis Gent
Universitair Ziekenhuis Gent
Ghent, Belgium21 results · Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Study Evaluating the Long-term Safety and Efficacy of VX-121 Combination Therapy | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Digestive System Diseases, Infant, Newborn, Diseases, cystic fibrosis, hereditary disease, lung disorder, pancreas disorder, respiratory system disorder | Active, not recruiting | Phase 3 | 2026-10-09 | NCT05444257 | |
| Study to Evaluate Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) Long-term Safety and Efficacy in Subjects Without F508del | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Digestive System Diseases, Infant, Newborn, Diseases, cystic fibrosis, hereditary disease, lung disorder, pancreas disorder, respiratory system disorder | Active, not recruiting | Phase 3 | 2026-10-09 | NCT05331183 | |
| Follow-up in Gynecological Cancer Survivors | female reproductive organ cancer | Active, not recruiting | Not stated | 2026-10-07 | NCT03515993 | |
| Study of SRP-1003 in Participants With Type 1 Myotonic Dystrophy | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Muscular Disorders, Atrophic, hereditary disease, inherited neurodegenerative disorder, muscle tissue disorder, muscular dystrophy, musculoskeletal system disorder, myotonic dystrophy, myotonic syndrome, nervous system disorder, neurodegenerative disease, neuromuscular disease | Enrolling by invitation | Phase 1 / Phase 2 | 2026-10-05 | NCT06138743 | |
| Open Label Extension to Assess Long Term Safety and Efficacy of KL1333 in Patients With Primary Mitochondrial Disease | Nutritional and Metabolic Diseases, inborn mitochondrial metabolism disorder, metabolic disease | Recruiting | Phase 2 | 2026-09-16 | NCT07514338 | |
| Neurovascular Product Surveillance Registry | Aneurysm, brain aneurysm, brain disorder, cardiovascular disorder, central nervous system disorder, cerebrovascular disorder, intracranial arterial disease, ischemic stroke, nervous system disorder, stroke disorder, vascular disorder | Recruiting | Not stated | 2026-09-15 | NCT02988128 | |
| Interfant-21 Treatment Protocol for Infants Under 1 Year With KMT2A-rearranged ALL or Mixed Phenotype Acute Leukemia | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, Precursor Cell Lymphoblastic Leukemia-Lymphoma, acute biphenotypic leukemia, hematologic disorder, immune system disorder, immunoproliferative disorder, leukemia, lymphatic system disorder, lymphoid leukemia, lymphoproliferative syndrome, mixed phenotype acute leukemia, neoplasm | Recruiting | Phase 3 | 2026-07-10 | NCT05327894 | |
| Study of Tinengotinib VS. Physician's Choice a Treatment of Subjects With FGFR-altered in Cholangiocarcinoma | Neoplasms by Histologic Type, adenocarcinoma, carcinoma, cholangiocarcinoma, epithelial neoplasm, neoplasm | Active, not recruiting | Phase 3 | 2026-07-06 | NCT05948475 | |
| Efficacy of KL1333 in Adult Patients With Primary Mitochondrial Disease | Muscle Weakness, Neurologic Manifestations, Neuromuscular Manifestations, Nutritional and Metabolic Diseases, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, diabetes mellitus, endocrine system disorder, glucose metabolism disease, metabolic disease, muscle tissue disorder, musculoskeletal system disorder, nervous system disorder, neuromuscular disease | Recruiting | Phase 2 | 2026-06-26 | NCT05650229 | |
| A Phase 3 Trial of Epcoritamab vs Investigator's Choice Chemotherapy in Relapsed/Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL) | B-cell neoplasm, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, diffuse large B-cell lymphoma, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, neoplasm | Active, not recruiting | Phase 3 | 2026-05-22 | NCT04628494 | |
| Efficacy and Safety of Obefazimod in Subjects With Moderately to Severely Active Crohn's Disease | Crohn disease, Digestive System Diseases, digestive system disorder, gastroenteritis, inflammatory bowel disease, intestinal disorder | Recruiting | Phase 2 | 2026-04-27 | NCT06456593 | |
| Safety and Efficacy of Quizartinib in Children and Young Adults With Acute Myeloid Leukemia (AML), a Cancer of the Blood | Disease Attributes, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Recurrence, acute myeloid leukemia, hematologic disorder, leukemia, myeloid leukemia, neoplasm | Active, not recruiting | Phase 1 / Phase 2 | 2026-04-01 | NCT03793478 | |
| Assess Safety and Efficacy of VAD044 in HHT Patients | Cardiovascular Abnormalities, Congenital Abnormalities, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Hemic and Lymphatic Diseases, arteriovenous hemangioma/malformation, cardiovascular disorder, hematologic disorder, hemorrhagic disease, hereditary hemorrhagic telangiectasia, telangiectasis, vascular disorder, vascular hemostatic disease, vascular malformation | Active, not recruiting | Phase 1 / Phase 2 | 2026-03-17 | NCT05406362 | |
| Phase 1/2 Study of IMC-R117C in Selected Advanced Cancers | cancer, neoplasm | Recruiting | Phase 1 / Phase 2 | 2026-01-28 | NCT06840119 | |
| Breast Implant-associated Anaplastic Large Cell Lymphoma (BIA-ALCL) Registry | Anaplastic Large Cell Lymphoma Associated With Breast Implants (BIA-ALCL) | Recruiting | Not stated | 2026-01-14 | NCT04220970 | |
| Motiva Flora® Aesthetic Breast Recon® Clinical Study | Bone Diseases, Developmental, Congenital Abnormalities, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Limb Deformities, Congenital, Musculoskeletal Abnormalities, Neoplasms by Site, Poland syndrome, Skin and Connective Tissue Diseases, bone disorder, breast cancer, breast disorder, breast neoplasm, dysostosis, musculoskeletal system disorder, neoplasm, skin disorder, syndactyly, synostosis | Recruiting | Not applicable | 2025-11-26 | NCT06146231 | |
| OligoCare TwiCs (Trials Within Cohorts) Trial Comparing Acute Toxicity in Single-fraction vs Multiple-fraction SBRT for Metastasis-directed Treatment (SPRINT) | Digestive System Diseases, Digestive System Neoplasms, Genital Diseases, Male Urogenital Diseases, Neoplasms by Site, Skin and Connective Tissue Diseases, Urogenital Diseases, Urogenital Neoplasms, breast cancer, breast disorder, breast neoplasm, colonic disorder, colorectal cancer, colorectal neoplasm, digestive system disorder, digestive system neoplasm, intestinal disorder, male reproductive organ cancer, male reproductive system disorder, neoplasm, non-small cell lung carcinoma, prostate cancer, prostate disorder, rectal disorder, skin disorder | Recruiting | Not applicable | 2025-08-01 | NCT06462963 | |
| Oral Pooled Fecal Microbiotherapy to Prevent Allogeneic Hematopoietic Cell Transplantation Complications (PHOEBUS Trial) | Transplant Complication | Recruiting | Phase 2 | 2024-12-27 | NCT05762211 | |
| MaaT013 As Salvage Therapy in Ruxolitinib Refractory GI-aGVHD Patients | Acute Graft Versus Host Disease in Intestine; Steroid Refractory GVHD | Active, not recruiting | Phase 3 | 2024-10-17 | NCT04769895 | |
| Subcutaneous Infliximab After A Previous Intravenous Dose Optimization | Crohn disease, Digestive System Diseases, colitis, colonic disorder, digestive system disorder, gastroenteritis, inflammatory bowel disease, intestinal disorder, ulcerative colitis | Recruiting | Phase 4 | 2024-07-26 | NCT06113913 | |
| FaR-RMS: An Overarching Study for Children and Adults With Frontline and Relapsed RhabdoMyoSarcoma | Myosarcoma, Neoplasms by Histologic Type, Neoplasms, Connective and Soft Tissue, myomatous neoplasm, neoplasm, rhabdomyosarcoma, sarcoma | Recruiting | Phase 1 / Phase 2 | 2024-05-23 | NCT04625907 |